Home » Newsletters » BioWorld Science

BioWorld Science

June 13, 2001

View Archived Issues

Phase II study shows NS-2330 capable of improving cognitive function in Alzheimer's patients

Genentech reacquires rights to growth hormone products from Schwarz

Clinical trials of NMP-66 for early detection of breast cancer open in Germany

Gilead begins phase I study of adefovir dipivoxil in China for treatment of HBV

Role for melatonin in Rx of periodontal disease discussed at IBMS/ECTS meeting

Neotrofin protects against kainic acid-induced neuronal injury in rodent model

NIH awards Direct Therapeutics SBIR grant

Vaxfectin enhances humoral immune response without affecting cell-mediated response to pDNA vaccines

Vasogen and CANVAC enter research alliance for immune modulation therapy

Endovasc studies new topical use of Liprostin

Pediatric pneumococcal conjugate vaccine approved in Canada

Nonviral hemophilia A gene therapy appears feasible according to phase I data

Enrollment in second rubitecan trial completed, triggering milestone payment

E.C. approves Amgen's ARANESP

Biogen's Amevive successfully completes phase III trials

Adenoviral transfer of PTEN as a promising anticancer gene therapy

pHyde, a new target gene in the treatment of prostate cancer

Rapid and progressive response to Elmiron reported in IC patients at AUA meeting

First launch for Myocet, a new breast cancer therapy

Company Profile: BioVex

COX-2 selective antiinflammatory agents in the Yakult Honsha portfolio

New prostaglandin derivatives useful for nephropathies and cardiovascular diseases

Vitamin D derivatives patented by Nisshin Flour Milling

Novel taxanes with improved profile designed at Daiichi

Preparation and methods of use of new uPAR antagonists

Analgesic activity demonstrated for Banyu's new muscarinic M4 receptor agonists

Takeda compounds inhibit testosterone synthesis, useful for sex steroid-dependent disorders

Fujisawa presents new antimicrobial cyclic hexapeptides

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....